On the one hand, α-melittin-NPs retained the characteristics of melittin that promoted the release of whole-tumor antigens in situ, and we also confirmed that the variety of immunogenic epitopes provided by whole-tumor antigens could activate both CD4+ and CD8+ tumor-specific T cells. This evidence concerns the gene CD4 and neoplasm.